Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2809185 | 0.87 | CYP1A2 (0.39) | SMN1; SMN2TSHRCYP1A1CYP1A2CYP1B1 | |
| SCHEMBL3644296 | 0.83 | ESR2 (0.40) | SMN1; SMN2HIF1ATSHRCYP19A1CYP1A1 | |
| SCHEMBL29513232 | 0.80 | CYP19A1 (0.46) | SMN1; SMN2TSHRCYP19A1CYP1A1CYP1A2 | |
| SCHEMBL899 | 0.80 | CYP19A1 (0.46) | SMN1; SMN2TSHRCYP19A1CYP1A1CYP1A2 | |
| SCHEMBL5684070 | 0.80 | ANPEP (0.46) | SMN1; SMN2TSHRCYP19A1ALDH1A1MAPT | |
| SCHEMBL584957 | 0.79 | CYP1A1 (0.39) | SMN1; SMN2MAOBTSHRCYP1A1CYP1A2 | |
| SCHEMBL3053661 | 0.79 | TSHR (0.35) | SMN1; SMN2TSHRCYP19A1CYP1A1CYP1A2 | |
| SCHEMBL11524213 | 0.79 | GABRA1 (0.41) | SMN1; SMN2HIF1AMAOAMAOBTSHR | |
| SCHEMBL1232356 | 0.79 | GABRA1 (0.37) | SMN1; SMN2TSHRCYP19A1CYP1A1CYP1A2 | |
| SCHEMBL6958245 | 0.79 | CA1 (0.37) | SMN1; SMN2HIF1AMAOAMAOBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1687034-A | Synthesis method of 4-phthalimide methyl phthalonitrile | UNIV FUZHOU (CN) | 2005-10-26 | — | — | CN | claimed |
| EP-2284157-A1 | Quinolines useful in treating cardiovascular disease | Wyeth (US) | 2011-02-16 | — | — | EP | disclosed |
| US-7576215-B2 | Quinolines and pharmaceutical compositions thereof | WYETH (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1692111-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | Wyeth, A Corporation of the State of Delaware (US) | 2006-08-23 | — | — | EP | disclosed |
| CN-1687034-A | Synthesis method of 4-phthalimide methyl phthalonitrile | UNIV FUZHOU (CN) | 2005-10-26 | — | — | CN | disclosed |
| WO-2005058834-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | WYETH (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | WYETH (US) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | NR1H2, NR1H3, SREBF1 | SMN1; SMN2 4482/4885HIF1A 1394/4885MAOA 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.